# Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

> **NCT04137900** · PHASE1 · UNKNOWN · sponsor: **TopAlliance Biosciences** · enrollment: 499 (estimated)

## Conditions studied

- Advanced Unresectable Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** TAB004
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04137900
- **Lead sponsor:** TopAlliance Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-30
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 499 (ESTIMATED)
- **Last updated:** 2024-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137900, "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04137900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*